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W e report the case of an 80-year-old Caucasian male, with
medical history of several episodes of
transient ischemic attack between Jan-
uary and September 2016. Investigation
with carotid ultrasound revealed fibrous
atheromatous plaque in both internal
carotidarterieswithseverestenosisonthe
left. The patient was proposed for left
internal carotid angioplasty and stenting
(CAS)andstartedonclopidogrel(75 mg/
day) and acetylsalicylic acid (100 mg/
day) one week before the procedure. His
medical record was also remarkable for
arterial hypertension, dyslipidemia, gall-
stones and sigmoidal adenocarcinoma
(submitted to surgery in 2008).
After an uneventful CAS procedure,
the guiding catheter was removed, and a
closure device was placed on the femoral
puncture site. At that time, the patient
complained of complete visual loss in his
left eye. Five minutes later, ophthalmic
examination of the left eye revealed visual
acuity (VA) of light perception, absolute
afferent pupillary defect and indirect oph-
thalmoscopy showed the presence of a
white thrombus in central retinal artery
inferior branch. The patient immediately
received 10 mg of abciximab bolus in
saline solution at 84 ml/hr and 500 mg
of acetazolamide. Vigorous eyeball mas-
sage was also performed. Ten minutes
later, he started a continuous infusion of
abciximab adjusted to his weight (3.75 ml
in50 mlofsalinesolutionat3.8 ml/hr).As
he was hemodynamically unstable (blood
pressureof90/60 mmHg),hecouldnotbe
transported to another hospital to start
hyperbaric chamber therapy. Forty-five
minutes after the initial complaint, the
patient claimed, and he had recovered his
vision. In fact, at that moment, VA was
counting fingers and indirect ophthal-
moscopydisclosedanyvascularocclusion,
and the retina had normal colour. Two
weeks later, his left eye corrected distance
VA in Snellen scale was 10/10 (2) with
+0.50 + 2.00@ 180°, equal to those mea-
sured 26 months before; fluorescein
angiography revealed no signs of vascular
disease, emboli or ischemia; and optical
coherence tomography (OCT) (macula,
optical disc, temporal and nasal superior
and inferior branches and surrounding
areas distancing until 2 mm)was normal.
Central retina artery occlusion
(CRAO) is an ocular emergency, and
actually there are no clinical trials to
determine if any treatment is effective
(Hedges et al. 2016). Conservative thera-
pies include: ocularmassage and/or ante-
rior chamber paracentesis in order to
increase retinalperfusion; carbonicanhy-
drase inhibitors, hyperosmotic diuretics,
topical sympathomimetic or beta-adre-
nergic blocking agents to reduce intraoc-
ular pressure; and hyperbaric oxygen to
improve oxygen delivery. In its updated
review, Hedges et al. also claimed that
conservative therapies were considered
futile. Nevertheless, Stefansson et al.
(1985)reportedacaseofmassiveembolus
of central retinal artery, treated with
anterior chamber paracentesis and
coughing, that resulted in restoration of
retinal blood flow; however, in this case
afferentpupillarydefectremainedpresent
and angiography revealed occlusion of
the inferior temporal arteriole with local
retinal oedema. More recently, another
successful conservative treatment of a
likely central retinal artery thromboem-
bolismafter internalcarotidarteryaneur-
ysmcoilocclusionwasreported;however,
in this caseauthors reported thatmultiple
small emboli could be seen within the
peripheral branches of the retina. More-
over, both afferent pupillary defect and
post-treatment angiography findings
werenotdescribed(Duxburyet al. 2014).
Systemic intravenous and local intra-
arterial fibrinolytic therapies are now
considered valid in many cases, despite
controversial (Schrag et al. 2015; Page
et al. 2016). As the patient was hemody-
namically unstable, and the femoral
access has already been closed with the
Angio-Sealclosuredevice,systemicabcix-
imabwas administered (Barreto 2012).
Abciximab was the first glycoprotein
IIb/IIIa inhibitor (GPI) approved by the
FDA.Theglycoprotein IIb/IIIa integrin
receptor is the pivotal mediator of
platelet aggregation, becoming abun-
dant on the platelet surface when plate-
lets are activated. In late 1990s, the
introduction ofGPIwas associatedwith




antibody Fab fragment. The binding of
abciximab to the platelet prevents the
interaction with other adhesive protein
molecules (Usta et al. 2016).
The most relevant point concerning
thiscasereport is thefindingthatsystemic
intravenous abciximab may represent a
novelandpromptapproachinemergency
room to CRAO induced by highly suspi-
cious platelet thrombus. This is particu-
larly relevant in centres with no
neuroendovascularfacilitiesorinpatients
where intra-arterialfibrinolytic therapy is
not recommended. The potential effects
of this approach in distal branch retinal
artery occlusion (not accessed by cathe-
ter) may also be considered.
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